Producing new fibrinolysin from rhizopchin

Abstract

The present invention relates to the extraction of fibrinolysin as new type of thromboliytic medicine from rhizopchin. The fibrinolysin has molecular weight 30.5 KD, isoelectric point 8.5, and double effects of directly dissolving thrombus and activating human plasminogen. The production process includes three stages, of culture of rhizopchin including slant culture, seed culture and fermentation culture; and separating and purifying fermented liquid to obtain fibrinolysin. The product is safe, non-toxic and cheap and the production process uses cheap agricultural side product as main material and is a liquid fermentation process. The purification process includes microfiltering to eliminate thallus, decolorizing with ion exchange resin, salting out, ultrafiltering to eliminate salt and hybrid protein and ion exchanging to purify. The present invention has short technological process, low cost and high production efficiency.

Description

technical field

[0001] The invention belongs to the technical field of biopharmaceutical production, and in particular relates to a novel plasminase produced by rhizopus sinensis and a method thereof. Background technique

[0002] Cardiovascular and cerebrovascular diseases, such as acute myocardial infarction and cerebral thrombosis, are one of the three major diseases that cause human death, and their incidence rates are increasing. The main component of thrombus is fibrin. Thrombolytic therapy is to dissolve the main matrix fibrin in thrombus by drugs, or activate the inactive plasma plasminogen in the blood to form active plasmin to catalyze the formation of fibrin. The hydrolysis of the thrombus dissolves and recanalizes blood vessels. Thrombolytic therapy is known as one of the top ten discoveries in cardiovascular and cerebrovascular sciences in the 20th century, and has been highly valued by various countries. The development of high...